NanoPhoria
NanoPhoria is an early-stage biotech startup dedicated to pioneering inhalable cardiovascular treatments through non-viral nano-delivery of biologics. Their mission is to develop a proprietary platform for tissue-directed delivery of therapeutic peptides and RNAs, utilizing inorganic calcium-phosphate nanoparticles as versatile, biomimetic nano-carriers. Their lead product, NP-MP1, is an inhalable nano-in-micro formulation aimed at treating Heart Failure with reduced Ejection Fraction (HFrEF) by modulating calcium channels in cardiomyocytes, thereby restoring heart function.
Industries
Nr. of Employees
small (1-50)
NanoPhoria
Via Visconti di Modrone, 18, 20122 Milan, Italy
Products
Inhalable nano‑in‑micro dry powder delivering a mimetic peptide for cardiomyocyte targeting
A three‑level dry powder formulation in which mimetic peptides are loaded into calcium‑phosphate nanoparticles that are embedded in lung‑compatible mannitol microparticles; designed for inhalation to deposit in alveoli, release nanoparticles into the bloodstream and enable cardiac uptake and intracellular peptide release.
Inhalable nano‑in‑micro dry powder delivering a mimetic peptide for cardiomyocyte targeting
A three‑level dry powder formulation in which mimetic peptides are loaded into calcium‑phosphate nanoparticles that are embedded in lung‑compatible mannitol microparticles; designed for inhalation to deposit in alveoli, release nanoparticles into the bloodstream and enable cardiac uptake and intracellular peptide release.
Expertise Areas
- Pulmonary drug delivery
- Nano‑delivery platforms (inorganic nanoparticles)
- Inhalation formulation development (nano‑in‑micro dry powders)
- Peptide therapeutic design
Key Technologies
- Calcium‑phosphate nanoparticle carriers
- Nano‑in‑micro dry powder inhalation
- Mannitol‑based inhalable microparticles
- Peptide mimetic therapeutics
News & Updates
NanoPhoria Bioscience was awarded €17.5 million from the European Innovation Council’s Accelerator Program.
NanoPhoria Bioscience was awarded €17.5 million from the European Innovation Council’s Accelerator Program.